UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 18, 2004
Biogen Idec Inc.
| Delaware | 0-19311 | 33-0112644 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
14 Cambridge Center, Cambridge, Massachusetts 02142
(Address of principal executive offices) (zip code)
Registrant’s telephone number, including area code: (617) 679-2000
Not Applicable
(Former name or former address, if changed since last report)
| ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE. | ||||||||
| ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS. | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EX-99.1 PRESS RELEASE DATED FEBRUARY 18, 2004 | ||||||||
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.
On February 18, 2004, the Registrant and Elan Corporation, plc publicly disseminated a joint press release announcing that they intend to submit to the U.S. Food and Drug Administration an application for approval of ANTEGREN® (natalizumab) as a treatment for multiple sclerosis in mid-year 2004. The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
99.1 The Registrant’s Press Release dated February 18, 2004.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Biogen Idec Inc. | ||
| (Registrant) | ||
| Date: February 19, 2004 | /s/ Anne Marie Cook | |
|
|
||
| Anne Marie Cook | ||
| Vice President, Chief Corporate Counsel |
3
EXHIBIT INDEX
| Exhibit | ||
| Number | Description | |
| 99.1 | The Registrant’s Press Release dated February 18, 2004. |
4